Latest News

New Drugs Getting FDA's Blessing Faster, but Is That a Good Thing?




fda

The result is that patients are being prescribed pricey new medications that have not been tested as rigorously, said lead researcher Jonathan Darrow, an assistant professor at Harvard Medical School.

Source link




Related posts

STAT Plus: To lower drug costs, CMS wants Medicare Part D plans to loosen formularies

Newsemia

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis

Newsemia

Health Tip: Hearing Loss Prevention

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy